study to assess the efficacy of xpro1595 in patients with mild cognitive impairment with biomarkers of inflammation

Conditions: Mild Cognitive Impairment (MCI); Alzheimer Disease; Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Mental Disorders

Summary: the goal of this phase 2 mci study is to determine whether 1.0 mg/kg xpro1595 is superior to placebo at improving measures of cognition, functioning and brain quality in individuals with mci and biomarkers associated with neuroinflammation (apoe4) and to evaluate safety, tolerability, and efficacy of xpro1595.

this study is designed as a phase 2, double-blind randomized, placebo-controlled study investigating the safety, tolerability, and efficacy of xpro1595 in patients with mci. the planned dose is 1.0 mg/kg of xpro1595 and matching placebo.

Eligibility criteria:
inclusion criteria: patients are eligible to be included in the study only if all the following criteria apply: * adult male and female patients ≥ 55 years to ≤ 80 years of age at the time of consent; * diagnosed with mci of probable alzheimer's disease (albert 2011; national institute on aging - alzheimer's association \[nia-aa\]). patients who have received previous therapy for alzheimer's disease may still be eligible; * amyloid positive (documented in medical history or assessed during screening through blood test); * literate and capable of reading, writing, and communicating effectively with others, based on the pi's assessment; * has a study partner willing to participate for the duration of the trial who either lives in the same household or interacts with the patient at least 4 hours per day and on at least 4 days per week, who is knowledgeable about the patient's daytime and night-time behaviors and who can be available to attend all clinic visits in person at which informant assessments are performed. exclusion criteria: * have any contraindications to mri scanning, including cardiac pacemaker/defibrillator, ferromagnetic metal implants (e.g., in-skull and cardiac devices other than those approved as safe for use in mri scanners at the strength required for this study); * receives considerable help to carry out basic adl living either in the home or as a resident in a nursing home or similar facility; * lifetime history of a major psychiatric disorder including schizophrenia and bipolar disorder. major depressive disorder that has resulted in 2 or more hospitalizations in a lifetime. major depressive episode during the past 5 years that is judged by the clinical team unlikely to have been part of alzheimer's prodrome. history of suicidality: has answered "yes" to columbia-suicide severity rating scale (c-ssrs) suicidal ideation items 4 or 5, or any suicidal behavior within 6 months before screening, at screening, or at the week 1 visit, or has been hospitalized or treated for suicidal behavior in the past 5 years before screening; * history of substance abuse within 12 months; use of cannabis or cannabis products within 6 months of consent; * enrolled in another clinical trial where patients receive treatment with an investigational drug or treatment device or have received treatment on another ad clinical trial within the last 60 days from day 1

Keywords: inflammation biomarker tumor necrosis factor (tnf)